Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Director | December 15, 2021 | December 17, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date December 15, 2021 · Filed December 17, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 77,332 |
Reported balance
After 2021-12-15 transaction · row 1
1 source rowRow 1 · 2021-12-15 · Grant · Acquired 12,000 · Balance 77,332 F1: Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2021 Filed Dec 17, 2021 22:04 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-151218 · tm2135659-5_4seq1.xml · nonDerivative · entry 1 TAUB MALCOLM S · CIK 0001305117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,332 F1 · shares: Shares acquired are shares of restricted stock awarded in connection with the Company's 2021 Annual Meeting of Stockholders pursuant to the Company's Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested on the first anniversary of December 15, 2021. Read SEC document |
| December 10, 2021 Filed Dec 11, 2021 01:04 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-148752 · tm2135032-7_4.xml · nonDerivative · entry 1 TAUB MALCOLM S · CIK 0001305117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,332 F1 · shares: Shares acquired are shares of restricted stock awarded effective November 11, 2020 in connection with the Company's 2020 Annual Meeting of Stockholders, pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vested in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested on the first anniversary of November 11, 2020, provided that the reporting person remained a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| December 12, 2019 Filed Feb 14, 2020 22:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-021981 · tm205737d1_4.xml · nonDerivative · entry 1 TAUB MALCOLM S · CIK 0001305117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,332 F1 · shares: Shares acquired are shares of restricted stock awarded on December 12, 2019 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on January 12, 2020 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director (and committee member, as applicable) of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| November 30, 2018 Filed Nov 30, 2018 22:01 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-062649 · tv507901_4.xml · nonDerivative · entry 1 TAUB MALCOLM S · CIK 0001305117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,332 F1 · shares: Shares acquired are shares of restricted stock awarded on November 30, 2018 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 30, 2018 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 21:37 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-058398 · tv479018_4.xml · nonDerivative · entry 1 TAUB MALCOLM S · CIK 0001305117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,332 F1 · shares: Shares acquired are shares of restricted stock awarded on November 10, 2017 pursuant to the Brainstorm Cell Therapeutics Inc. Second Amended and Restated Director Compensation Plan. The shares of restricted stock vest in 12 consecutive, equal monthly installments commencing on December 10, 2017 until fully vested on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.